|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We also found no evidence for a significant association of rs10046 genotypes with breast cancer prognosis.
|
29363090 |
2018 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A significant association was observed between the rs10046 polymorphism of the CYP19gene and breast cancer in Iranian patients.
|
27165202 |
2016 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygotes of minor alleles of CYP19 rs10046 (CC) were associated with a reduced risk of BC with OR: 0.61 (95%CI = 0.39-0.95).
|
27323034 |
2016 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, breast cancer in Xinjiang Uigur women is closely connected with the age, BMI, parity, abortion, and CYP19 rs10046 polymorphisms.
|
26345775 |
2015 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No rs10046 genotypes were significantly associated with increased breast cancer risk or patient character</span>istics other than age at onset.
|
24402127 |
2014 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We can conclude that the rs10046 polymorphism on CYP19 by itself does not constitute breast cancer risk.
|
23342035 |
2013 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study provides evidence that polymorphisms CYP17 rs743572, CYP19 rs10046 and ER-alpha rs3798577 are associated with breast cancer risk among Chinese women.
|
18629629 |
2009 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.
|
18049890 |
2008 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The present study indicates that CYP19 rs464</span>6 polymorphism is related to DFS in early breast cancer and that the prognosis index of the homozygous for the minor allele (AA) may depend on menopause status.
|
25793413 |
2015 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
These findings suggest that the presence of the rs4646 variant may be a predictive factor of the benefit of AI treatment for BC.
|
26067721 |
2015 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The homozygous minor allele (AA) of CYP19A1 rs4646 is significantly associated with improved clinical outcome of hormone therapy in premenopausal HR-positive early breast cancer patients, but with a worse impact on postmenopausal women.
|
26191232 |
2015 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
The common allele of rs4646, which has been associated with increased breast cancer risk, was associated with low-histological grade and small tumour size (P = 0.001 and 0.015; 1-sided, respectively).
|
20960227 |
2011 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Testing for the rs4646 polymorphism could be a useful tool in order to orientate the treatment in elderly BC patients.
|
20144226 |
2010 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Testing for the CYP19 rs4646 SNP as a predictive tool for breast cancer patients on antiaromatase therapy deserves prospective evaluation.
|
18245543 |
2008 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
rs4646
|
|
|
0.090 |
GeneticVariation |
BEFREE |
SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.
|
18049890 |
2008 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In addition, a stratified analysis by menopausal status indicated that the association of the CYP19 polymorphisms (rs10046 and rs700519) with BC risk was mainly evident in premenopausal women, and the association of CYP19 rs700519 with BC risk was significant in women less than 50 years old.
|
27323034 |
2016 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our findings suggest that rs700519 and rs2069522 are associated with susceptibility to breast cancer among the Han Chinese population and have a cumulative effect with three other identified SNPs.
|
25689428 |
2015 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We examined the association of single nucleotide polymorphism (SNP) in estrogen receptors, ESR1 (rs2234693) and ESR2 (rs2987983); estrogen biosynthesis enzymes, CYP17A1 (rs743572); and aromatase, CYP19A1 (rs700519) with breast cancer risk.
|
24430361 |
2014 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A DNA bank of patients with gynecologic oncology, patients with breast cancer (n = 335), and healthy women (n = 530) was created, and the following single-nucleotide polymorphisms were examined: CYP1A1 M1 polymorphism, that is, T264-C transition in the 30-noncoding region; CYP1A2*1F polymorphism, that is, C734-A transversion in the CYP1A2 gene; C-T transition (Arg264Cys) in exon 7 of CYP19; and SULT1A1*2 polymorphism, that is, G638-A transition (Arg213His) in the SULT1A1 gene.
|
21977969 |
2012 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A total of 22 studies with 10,592 cases and 11,720 controls were identified, and the results showed that R264C polymorphism was not associated with breast cancer risk in overall (T vs. C: OR = 1.061, 95% CI = 0.929-1.212) or race-based populations (T vs. C for Asian: OR = 1.169, 95% CI = 1.002-1.363; for Caucasian: OR = 0.787, 95% CI = 0.597-1.037); meanwhile, for Asian individuals, 3-bpDel/Ins polymorphism showed a significantly association with breast cancer susceptibility (for allele Del vs. allele Ins: OR = 1.278, 95% CI = 1.066-1.532) while the carriers of allele (TTTA)(12) can significantly decrease breast cancer risk (OR = 0.752, 95% CI = 0.603-0.939).
|
20052540 |
2010 |